Indefinite Delivery Contract SPE2DU25D9122

Award Date 8/1/25
Last Date to Order 12/31/36
Ultimate Awardee
Not listed
Federal Contract Vehicle
Pricing Type
Firm Fixed Price
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Single
Primary Consortia Member
Not listed
Similar IDVs
The federal contract IDV awarded to DMS Pharmaceutical Group Inc. is a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 with the Defense Logistics Agency (DLA) under the SPE2DB program. The contract covers a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the recurring medical supply needs of military healthcare facilities and veterans' medical...
The key products and services being delivered under this federal contract IDV award to DMS Pharmaceutical Group Inc. are pharmaceutical and medical supply items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables. This single-award Indefinite Delivery Contract (IDC) with a ceiling value of $4,999,999 was issued by the Defense Logistics Agency (DLA) under the SPE2DB program, with a period of performance from November 2025 through...
The federal contract IDV award to DMS Pharmaceutical Group Inc. is a single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical...
The Defense Logistics Agency (DLA) has awarded a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. This IDC, under the SPE2DB program, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply...
The federal contract IDV award to DMS Pharmaceutical Group Inc. is a single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency (DLA) under the SPE2DB program, valued at $499,999,999 and valid through November 2026. This IDC enables the DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical...
The federal contract IDV award SPE2DU25D9514 is a single-award Indefinite Delivery Contract (IDC) between the Defense Logistics Agency (DLA) and DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $499,999,999 IDC, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical...
The federal contract IDV award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, covers a wide range of pharmaceutical products and medical supplies to support the medical needs of Department of Defense (DoD) healthcare facilities and the U.S. Coast Guard. The single-award Indefinite Delivery Contract (IDC), valued at $499,999,999 and valid through November 2026, enables DLA to issue firm fixed-price delivery orders for branded and generic...
The federal contract IDV award from the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business, is a single-award Indefinite Delivery Contract (IDC) valued at $499,999,999 and valid through November 2026. The contract enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical...
The federal contract IDV awarded to DMS Pharmaceutical Group Inc. is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The IDC has a ceiling value of $499,999,999 and is valid through November 2026. Under this contract, DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, will provide a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical...
The Defense Logistics Agency (DLA) awarded a single-award Indefinite Delivery Contract (IDC) to DMS Pharmaceutical Group Inc., a woman-owned small business, to provide a comprehensive range of pharmaceutical products and medical supplies to support the recurring medical needs of military healthcare facilities and veterans' medical centers nationwide. The $499,999,999 IDC, valid through November 2026, covers an extensive portfolio of branded and generic prescription drugs, over-the-counter...

The federal contract IDV award to DMS Pharmaceutical Group Inc. is a single-award Indefinite Delivery Contract (IDC) issued by the Defense Logistics Agency (DLA) under the SPE2DB program. The $499,999,999 contract, valid through November 2026, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items, including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables, to support the medical supply needs of military health facilities worldwide.

The original solicitation, expected to be issued in March 2024, is for the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) contracts to provide worldwide pharmaceutical support to various Department of Defense (DoD) customers, including the Defense Health Agency, United States Coast Guard, and U.S. Naval Fleet. The unrestricted, fully competitive acquisition will result in multiple primary supplier awards for separate regions (North/EUCOM, West/PACOM, South/SOUTHCOM, and Fleet) and a single back-up supplier award, with the intention of ensuring resilient access to vital pharmaceuticals during contingencies or natural disasters.

Generated 6/6/25, 9:55 AM